Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
It's an acquisition that aims at forming one of the US's largest oncology trial networks
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Valorum will advance the commercialization and distribution of Armlupeg in the United States
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
Subscribe To Our Newsletter & Stay Updated
